Kevin Jao

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Catherine Labbé, Michael Cabanero, Grzegorz Korpanty et al. · Lung Cancer · 2017 · 246 citations

Medicine, Molecular Genetics, Oncology +15

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Arielle Elkrief, Antoine Desîlets, Neha Papneja et al. · European Journal of Cancer · 2020 · 83 citations · Full text

Medicine, Infectious Diseases, Oncology +17

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 78 citations

Medicine, Oncology, Radiation Oncology +14

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman et al. · Journal for ImmunoTherapy of Cancer · 2023 · 73 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17